Appointment Start Date
Online appointments begin on Saturday, September 13, 2025 via our clinic website.Web reservations begin
📅 Vaccination Period
Scheduled from Wednesday, October 1 to Saturday, December 27, 2025
🟢 Eligibility
Children and adolescents aged 2 to under 19 years
💉 Administration Method
One dose of 0.2 ml sprayed into both nostrils (0.1 ml per side)
💰 Cost
¥8,000 (tax included)
Akita City subsidy of ¥1,000 applies → out-of-pocket cost: ¥7,000
📱 How to Book
Appointments available via our website. Reservations will close once the supply limit is reached.
📋Request to Complete the Pre-Visit Questionnaire
• To help reduce waiting time at the clinic,we kindly ask that you complete the pre-visit questionnaire (internal link) in advance,except for the “body temperature” field, which will be measured upon arrival. Please print the completed form and bring it with you on the day of your visit.
• Akita City has decided to partially subsidize the cost of influenza vaccinations for children and pregnant women, effective October 1st.。
👶 Eligible Recipients
At the time of vaccination, individuals must be registered residents of Akita City and meet one of the following criteria:
📅 Subsidy Period
October 1, 2025 (Wednesday) to February 28, 2026 (Saturday)
Please note: Our clinic will offer vaccinations from October 1 to December 27, 2025.
• 💡 Differences in ApplicationProcedure Based on Vaccination Timing
🔀For vaccinations received October 1–16, 2025 (Reimbursement method)
•
Please pay the full vaccination fee at the clinic first. Then, apply for the subsidy through Akita City’s online application system.
Application deadline: March 31, Reiwa 8
[Electronic Application Form for Influenza Vaccination Subsidy (External link)]
🔀If vaccinated after October 17th, receive vaccination at a medical institution contracted with the city (agency receipt system).
- As in previous years, submit the application form to the clinic in advance.
Our clinic will handle the subsidy procedures on your behalf. No further steps will be required from you.
Please fill out the proxy authorization form using a non-erasable pen. Applications with corrected amounts cannot be accepted. If you make a mistake, please fill out a new form.
Please use the following power of attorney form or the one provided at our institution.
Influenza Vaccination Subsidy Application & Proxy Authorization Form (Excel, 17.7 KB)
This is the application and proxy authorization form. Please fill in the highlighted sections. The form is also available at our clinic.
Influenza Vaccination Subsidy Application & Proxy Authorization Form (PDF, 36.5 KB)
This is the handwritten version of the application and proxy authorization form. It is also available at our clinic.
Sample Completed Form (PDF, 46.9 KB)
This is a sample of how to fill out the application and proxy authorization form.
📝 Request to pre-fill the application form. Application forms have been available at our hospital's reception desk since October 1st.
To reduce congestion in the clinic, please complete the form before your visit and bring it with you on the day of vaccination.
💴 Subsidy Amount and Dosing
Subsidy amount: 1,000 yen per session
Children aged 6 months to under 13 years will receive a subsidy of 2,000 yen for two doses.
Pregnant women are eligible for one subsidized dose
🏥 For Residents Outside Akita City
• People living outside Akita City can also receive the influenza vaccine at our clinic.
You can receive subsidies for vaccination costs by applying to each municipality, so please feel free to inquire.
There are two main types of influenza vaccines. Both the World Health Organization (WHO) and the National Institutes of Health (NIH) recommend selecting the appropriate vaccine based on the patient’s age, health condition, and living environment.
| Comparison items | LAIV (FluMist®) | Inactivated vaccine |
| Vaccination method | Nasal spray (painless) | Subcutaneous injection (painful) |
| Target age | 2-18 years old (Japan) | From 6 months of age |
| Effectiveness | Equivalent | |
| Induces mucosal immunity (IgA) and excels at early infection defense. | Induces antibodies in the blood (IgG) and is excellent at preventing severe illness. | |
| Side effect | Runny nose, cough, etc., mild | Swelling, fever, etc. |
| Vaccination restrictions | Pregnant women and immunocompromised individuals are not allowed. | Widely available |
• In our experience, FluMist® may be a suitable option for children who have previously experienced significant swelling from injectable influenza vaccines, such as reactions extending beyond the elbow. Please consult with our staff to determine the best choice for your child.
🔗 Related Internal Links
🏙️ Announcement: 2025 Influenza Vaccination Appointments Now Open
- 🏙️ [Akita City Influenza Vaccination Subsidy Information]
🧓Senior Influenza Vaccination Guide – 2025
🛡️Frequently Asked Questions: Inactivated Influenza Vaccine vs. Nasal Spray (FluMist®)
References and Source MaterialsClick to view the recommended documents and guidelines.
• “Both LAIV and IIV are effective when matched to circulating strains. Selection should be based on age, health status, and epidemiological context.”
(Translation: Both LAIV and IIV are effective if they match the circulating strains. The choice should be made based on age, health status, and the current influenza situation.)
WHO FluNet Surveillance Dashboard
• FluMist. FDA Drug Label.
U.S. Food and Drug Administration (FDA) DailyMed
• Thwaites RS, Uruchurtu ASS, Negri VA, et al.
Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine - PubMed
Nature Communications. 2023;14(1):8053. doi:10.1038/s41467-023-43842-7
• Barría MI, Garrido JL, Stein C, et al.
Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults.
The Journal of Infectious Diseases. 2013;207(1):115–124. doi:10.1093/infdis/jis64
🌍 WHO (World Health Organization) Perspectives (2024 Edition)
🇺🇸 NIH (National Institutes of Health) and ACIP views (Spring 2025 Report): “LAIV is a safe and effective option for healthy individuals aged 2–49, but IIV remains the preferred choice for immunocompromised and pregnant populations.”
LAIV is a safe and effective option for healthy individuals aged 2-49, but IIV is recommended for immunocompromised individuals and pregnant women.
• CDC: Trivalent Influenza Vaccines
• 2024–2025 Flu Season
Japanese Pediatric Society's Stance (as of September 2, 2024)
• Considerations and Topics Regarding Influenza Vaccination for the 2024/25 Season
• Approach to the Use of Live Attenuated Influenza Vaccine (Nasal) (The Japan Pediatric Society - External Link)
• Regarding Influenza Vaccination for Children (Ministry of Health, Labour and Welfare External Committee Report)Pink
• Flumist Nasal Spray Package Insert (Daiichi Sankyo Document, External Link)
Check the latest information
